SSSamir Sahoo

Samir Sahoo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Samir Sahoo has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Ferroptosis in cancer: integrating multi-omics, AI-driven biomarkers, and translational challenges

    by Anmar Ghanim Taki, Abdulkareem Shareef, Vimal Arora, Rami Oweis, S. Renuka Jyothi, Udaybir Singh, Samir Sahoo, Ashish Singh Chauhan, Farzona Alimova, Hayder Naji Sameer, et al.


  • The efficacy of probiotics, prebiotics, and synbiotics in depression and anxiety: an umbrella review of clinical trials

    by Ghaleb Oriquat, Waleed K. Abdulsahib, Wael Waleed Mustafa, Jalpa R. Patel, K. V. Jamuna, Vandana Tripathi, Samir Sahoo, Neeraj Bainsal, Nigina Khalikova

  • Open Access

    Ubiquitination and deubiquitination as critical modulators of NSCLC tumorigenesis and drug resistance

    by Prasanna Srinivasan Ramalingam, Mohammad Afzal, Manjunath Mirle Rekha, Samir Sahoo, Surya Nath Pandey, Chandana Maji, Kavita Goyal, Haider Ali, Sachin Kumar Singh, Gaurav Gupta, et al.

    Ubiquitination and deubiquitination are biological mechanisms that including the addition and removal ubiquitin molecules from proteins, which are associated with NSCLC. NSCLC is the most common kind of lung cancer, and treatment resistance and cancer development are linked to these alterations. Ubiquitination incorporates proteins by a particular enzyme class, and deubiquitination removes ubiquitins. In NSCLC, this modification is detrimental to cellular function and affects tumorigenesis, apoptosis, and signaling pathways. Conversely, deubiquitination refers to the process through which the ubiquitins are removed from the proteins so that they can perform their functions properly. These processes can be considered therapeutic in some sense, as regulating both can result in an effective therapy for NSCLC. Many studies have been carried out to find potential areas where further drug research could be focused. This study examines the functions of ubiquitination and deubiquitination in NSCLC pathogenesis and resistance, focusing on their mechanisms, consequences, and therapeutic possibilities. Graphical Abstract

  • Open Access

    MicroRNA-mediated modulation of cancer-associated fibroblasts in HER2-positive breast tumor microenvironment: a comprehensive review

    by Mustafa T. Ardah, Waleed K. Abdulsahib, Hasanain Amer Naji, S. Renuka Jyothi, Samir Sahoo, J. Bethanney Janney, Vipasha Sharma, Aashna Sinha, Mohigul Kholiyeva

    The intricate interplay within the tumor microenvironment (TME) significantly dictates the trajectory of cancer progression and therapeutic response. In HER2-positive breast cancer, a particularly aggressive subtype, cancer-associated fibroblasts (CAFs) emerge as pivotal stromal components, actively orchestrating malignant behaviors. Concurrently, microRNAs (miRNAs), small non-coding RNAs, serve as potent post-transcriptional regulators and critical mediators of intercellular communication, often encapsulated within exosomes. This review provides a comprehensive analysis of the reciprocal miRNA-mediated modulation between HER2-positive breast cancer cells and CAFs. It elucidates how tumor cell-derived miRNAs reprogram normal fibroblasts into pro-tumorigenic CAFs, and how CAF-derived miRNAs, in turn, influence HER2-positive cancer cell proliferation, invasion, metastasis, and crucially, resistance to HER2-targeted therapies. Understanding this dynamic axis reveals a self-sustaining feedback loop that drives disease advancement and therapeutic evasion. This synthesis underscores the immense potential of targeting these complex miRNA-CAF interactions as a novel strategy for diagnostic, prognostic, and therapeutic interventions, aiming to overcome the persistent challenge of resistance in HER2-positive breast cancer.


  • Exosomal non-coding RNAs as emerging drivers of immune dysregulation in melanoma

    by Bahaa Ibrahim Saeed, Wesam R. Kadhum, Muhammad Ikram Ullah, Jaafaru Sani Mohammed, Suhas Ballal, Abhayveer Singh, D Alex Anand, Samir Sahoo, Yasser Fakri Mustafa, Hanen Mahmod Hulail

    Melanoma is a type of skin cancer that starts in melanocytes. It is estimated to increase by 2050 based on prediction studies. Exosomes have been identified as crucial intracellular mediators by carrying the donor-derived cargoes from stromal cells, immune cells, and even tumor cells, thereby affecting the function of recipient cells in a context-dependent manner. Although EVs can transport biologically active compounds like proteins, lipids, RNA, and DNA, their exact role remains unclear. The past few years have seen a surge in studies on tumor-associated cargo in exosomes, particularly concerning ncRNAs. The function of exosomal non-coding RNAs in melanoma’s immunopathogenesis has been reviewed in detail in the current narrative review article. Exosomal ncRNAs have the potential to develop novel diagnostic and therapeutic targets in melanoma.

  • The emerging role of miR-362 in cancer: expression and function across different cancer types

    by Shahad Mohammed Dhiaa Younis, Abdulkareem Shareef, Lalji Baldaniya, Rami Oweis, S. Renuka Jyothi, Udaybir Singh, Samir Sahoo, Ashish Singh Chauhan, Hayder Naji Sameer, Ahmed Yaseen, et al.

    MicroRNAs (miRNAs) are essential post-transcriptional regulators of gene expression involved in a broad range of biological activities. Recent studies have increasingly highlighted their significant role in the development and progression of various human cancers. Among these, miR-362 has emerged as a context-dependent molecule, exhibiting both oncogenic and tumor-suppressive functions across different malignancies. Elevated levels of miR-362 have been associated to tumor-promoting effects in several cancers. In contrast, its downregulation in some other carcinoma is associated with disease progression, suggesting a tumor-suppressive role. These opposing functions underscore miR-362 involvement in complex regulatory networks and supports its potential as a biomarker for diagnosis, prognosis, and possibly therapeutic intervention. This review aims to provide an overview of the current understanding of miR-362 expression patterns, molecular targets, regulatory mechanisms, and its dual role in cancer biology, with the goal of clarifying its clinical significance in cancer diagnosis, prognosis, and therapy. Graphical Abstract The specific targets of miR-362 across various malignancies


  • Exosomes as key mediators in immune and cancer cell interactions: insights in melanoma progression and therapy

    by Chou-Yi Hsu, Harish C. Chandramoorthy, Jaafaru Sani Mohammed, Shaker Al-Hasnaawei, Mohammed Yaqob, Mayank Kundlas, Krishnakumar Samikan, Samir Sahoo, S. K. Sunori, Zainab Ahmed Abbas

    Exosomes (30–150 nm) are small extracellular vesicles that are secreted by cells into the extracellular environment and are known to mediate cell-to-cell communication. Exosomes contain proteins, lipids, and RNA molecules in relative abundance, capable of modifying the activity of target cells. Melanoma-derived exosomes (MEXs) promote the transfer of oncogenic signals and immunosuppressive factors into immune cells, resulting in a bias of the immune response towards tumor-promoting processes. MEXs could suppress the activation and proliferation of T cells and dendritic cells and induce differentiation of myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). They can induce apoptosis of antigen-specific CD8 + T cells and promote the transfer of tumor antigens, resulting in immune evasion. Specifically, MEXs can shuttle cytokines like interleukin-10 (IL-10) and transforming growth factor-β (TGF-β) to immune cells or express programmed death-ligand 1 (PD-L1 or CD274), creating an immune-suppressive microenvironment that promotes tumorigenesis. Since exosomes preferentially accumulate in melanoma tissues, this targeted delivery could enhance the bioavailability of treatments while limiting side effects. Here, we review the molecular composition of melanoma-derived exosomes, their mechanisms of action, and their potential as therapeutic targets or biomarkers in melanoma. The summarizations of these mechanisms to appropriately influence exosome-mediated interactions could yield new tactics to elicit anti-melanoma immunity or augment the therapeutic effects of current therapies.